Cabaletta Bio (CABA) Capital Expenditures (2019 - 2025)
Cabaletta Bio (CABA) posted quarterly Capital Expenditures of -$43000.0 for Q3 2025, down 117.0% year-over-year from $253000.0 in Q3 2024, and up 94.2% quarter-over-quarter from -$742000.0 in Q2 2025.
Cabaletta Bio (CABA) Capital Expenditures (2019 - 2025) Analysis & Trends
Cabaletta Bio's Capital Expenditures history runs 7 years deep, the most recent figure standing at -$43000.0 for Q3 2025.
- In Q3 2025, Capital Expenditures fell 117.0% year-over-year to -$43000.0; the TTM figure through Sep 2025 stood at $376000.0 (down 81.52% YoY), while the FY2024 annual figure was $2.2 million, up 214.96% from the prior year.
- Capital Expenditures for Q3 2025 stood at -$43000.0, up from -$742000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $1.7 million in Q3 2022, with the low at -$2.1 million in Q4 2022.
- The 5-year median for Capital Expenditures is $261000.0 (2022), against an average of $226611.1.
- The sharpest annual moves came in 2021 and 2024: Capital Expenditures tumbled 374.07% in 2021, then surged 3900.0% in 2024.
- Cabaletta Bio's Capital Expenditures stood at $1.1 million in 2021, then slumped by 296.06% to -$2.1 million in 2022, then soared by 109.36% to $200000.0 in 2023, then soared by 88.0% to $376000.0 in 2024, then slumped by 111.44% to -$43000.0 in 2025.
- Business Quant data shows CABA's Capital Expenditures at -$43000.0 in Q3 2025, -$742000.0 in Q2 2025, and $785000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 205,000.00 |
| Dec 31, 2025 | 205,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Jun 30, 2025 | -742,000.00 |
| Jun 30, 2025 | -742,000.00 |
| Mar 31, 2025 | 785,000.00 |
| Mar 31, 2025 | 785,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Sep 30, 2024 | 253,000.00 |
| Jun 30, 2024 | 920,000.00 |
| Jun 30, 2024 | 920,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 479,000.00 |
| Sep 30, 2023 | 479,000.00 |